for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sangamo Therapeutics Inc

SGMO.OQ

Latest Trade

9.60USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.05

 - 

19.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.60
Open
--
Volume
--
3M AVG Volume
20.33
Today's High
--
Today's Low
--
52 Week High
19.41
52 Week Low
9.05
Shares Out (MIL)
143.88
Market Cap (MIL)
1,381.26
Forward P/E
-7.63
Dividend (Yield %)
--

Next Event

Q2 2021 Sangamo Therapeutics Inc Earnings Release

Latest Developments

More

Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, To CFO

Sangamo Therapeutics Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.32

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry

Biotechnology & Drugs

Contact Info

7000 MARINA BLVD

BRISBANE, CA

94005

United States

+1.510.9706000

https://www.sangamo.com/

Executive Leadership

H. Stewart Parker

Independent Chairman of the Board

Alexander D. Macrae

President, Chief Executive Officer, Director

Prathyusha Duraibabu

Chief Financial Officer, Senior Vice President

Gary H. Loeb

Executive Vice President, Chief Compliance Officer, General Counsel, Secretary

D. Mark McClung

Executive Vice President, Chief Business Officer

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.700

2019

-0.850

2020

-0.900

2021(E)

-1.272
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.51
Price To Book (MRQ)
2.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-19.58
Return on Equity (TTM)
-16.98

Latest News

Latest News

Pfizer's hemophilia gene therapy shows sustained effect in early-stage study

Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.

BRIEF-Sangamo Therapeutics Reports Q4 EPS Of $0.04

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Increased Size Of Board To Nine Members From Eight

* SANGAMO THERAPEUTICS INC - ON FEB 11, BOARD OF DIRECTORS INCREASED SIZE OF BOARD TO NINE MEMBERS FROM EIGHT Source: (https://bit.ly/3266fYZ) Further company coverage:

BRIEF-Sangamo Therapeutics Appoints John Markels To Board Of Directors

* SANGAMO THERAPEUTICS APPOINTS JOHN MARKELS TO ITS BOARD OF DIRECTORS

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

BioMarin sets stage early for hemophilia cure off-Broadway

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up